Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (FUDANZHANGJIANG) submitted its Monthly Return for Equity Issuers for the month ended 30 June 2026, confirming that both its H-share and A-share capital structures remained unchanged while meeting Hong Kong’s public-float requirements.

Registered Share Capital • H shares: 326.00 million shares at RMB 0.1 par value, equal to RMB 32.60 million. • A shares (STAR Market): 710.57 million shares at RMB 0.1 par value, equal to RMB 71.06 million. Total registered share capital: RMB 103.66 million.

Issued Shares and Treasury Position • Issued H shares: 326.00 million; issued A shares: 710.57 million. • No treasury shares were held across either class, and there were no share repurchases, cancellations, or issuances during the month.

Public Float Compliance The company affirmed compliance with Main Board Rule 13.32B’s public-float requirement for PRC issuers, maintaining at least 5% of its H-share class in public hands as of 30 June 2026.

Capital Instruments No outstanding share options, warrants, convertible securities, or other equity-linked instruments were reported. Additionally, the company has no Hong Kong Depositary Receipts in issue.

The filing underscores a stable capital structure for FUDANZHANGJIANG, with no equity dilution events in June 2026 and continued adherence to regulatory free-float standards.